Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enhabit, Inc. (NYSE: EHAB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer. Enhabit, which operates as Enhabit Home Health & Hospice, files reports with the U.S. Securities and Exchange Commission that describe its home health and hospice business, financial performance, governance matters, and executive compensation arrangements.
Through its Form 8-K filings, Enhabit reports material events such as quarterly earnings releases, participation in investor conferences, leadership changes, and stockholder meeting results. For example, the company has filed 8-Ks to furnish its earnings press releases and supplemental information for quarters ended March 31, June 30, and September 30, as well as to describe a CEO transition plan, retention awards for senior officers, and approval of the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan at its annual meeting.
Enhabit’s filings also identify its common stock as registered under Section 12(b) of the Exchange Act and traded on the New York Stock Exchange under the symbol EHAB. The company uses its SEC reports to explain its use of non-GAAP measures such as Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted EPS, and Adjusted free cash flow, and to discuss how unusual or nonrecurring items affect the reconciliation to GAAP results. Same-store comparison methodology for home health and hospice locations is also described in these materials.
On this page, users can review Enhabit’s SEC filings in chronological order, including 8-Ks that detail results of operations and financial condition, regulation FD disclosures, equity plan approvals, and stockholder voting outcomes. Stock Titan’s tools surface these documents alongside AI-powered summaries that highlight key points, helping readers quickly understand how each filing relates to Enhabit’s home health and hospice operations, capital structure, and governance.
Investors and researchers can use this filings archive to follow Enhabit’s reported net service revenue trends, segment performance, executive and director arrangements, and the regulatory context around its home-based care business, all sourced from the company’s official submissions to the SEC’s EDGAR system.
Enhabit (EHAB) reported a return to profitability in Q3 2025. Net service revenue was $263.6M, up 3.9% year over year. Operating income reached $16.8M versus a loss in the prior year, and net income attributable to Enhabit was $11.1M, or $0.22 per diluted share, compared with a loss of $110.2M a year ago, which included a goodwill impairment.
Hospice drove the quarter with revenue of $63.1M, up 20.0%, while Home Health was $200.5M, down 0.2%. Adjusted EBITDA was $27.0M versus $24.5M. For the first nine months, revenue was $789.6M (up 1.7%) and net income was $34.1M, helped by a $19.3M gain on sale of an investment. Interest expense fell with lower borrowings and rates.
Cash rose to $56.9M, and total debt was $463.8M, including $333.5M on the term loan and $125.0M drawn on the revolver. The company closed or consolidated 13 branches year‑to‑date and remained in compliance with credit facility covenants. CMS finalized a 2.6% hospice payment increase effective October 1, 2025, and proposed a 6.4% home health decrease for 2026.
Enhabit, Inc. furnished an 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025. The company also provided supplemental materials for its earnings discussion.
Exhibit 99.1 contains the earnings press release dated November 5, 2025, and Exhibit 99.2 includes supplemental information for the third quarter 2025 earnings call. The call is scheduled for 9:00 a.m. Eastern Time on Thursday, November 6, 2025. The materials under Items 2.02 and 7.01 are being furnished, not filed.
Enhabit, Inc. (EHAB) director Erin Hoeflinger purchased 2,969 shares of the company's common stock on
Enhabit, Inc. (EHAB) filed a Form 4 reporting a director’s share acquisition. On 10/10/2025, the reporting person acquired 2,969 shares of common stock at a price of $8 per share. Following this transaction, the filer beneficially owns 67,850 shares. Ownership is reported as direct.
Stuart M. McGuigan, a director of Enhabit, Inc. (EHAB), reported a purchase of 2,344 shares of the company's common stock on
Enhabit, Inc. (EHAB) director Gregory S. Rush acquired
Insider purchase reported: A director of Enhabit, Inc. (EHAB) acquired 2,344 shares of common stock on
Director Mark W. Ohlendorf reported a non-derivative purchase of 2,344 shares of Enhabit, Inc. (EHAB) on 10/10/2025 at a reported price of
Insider purchase reported: A Form 4 shows director Charles M. Elson acquired 2,344 shares of Enhabit, Inc. (EHAB) on
Insider purchase recorded on Form 4. A director, Jeffrey Bolton, purchased 4,688 shares of Enhabit, Inc. at
FAQ
What is the current stock price of Enhabit (EHAB)?
What is the market cap of Enhabit (EHAB)?
